Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat vs heparin for anticoagulation during hemodialysis
CTR20160384Phase 3Completed
- Sponsor
- Lanzhou Jinglong Pharmaceutical Technology
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Nafabelltan in end-stage kidney disease (ESKD), sponsored by Lanzhou Jinglong Pharmaceutical Technology. Started Sep 2016; status: completed.
02
Drugs
Nafabelltan
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on CTR20160384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160384.